Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma.
Antibodies directed against the beta chain of the T cell receptor (anti-Vbeta antibodies) are useful to identify the Vbeta repertoire of T cells in various diseases and to quantify numbers of Vbeta-bearing T cells. The goals of this study were to identify Vbeta+ cases of leukemic phase cutaneous T cell lymphoma (CTCL) and to compare the percentage of positive calls with other measures of blood tumor burden, i.e., lymphocyte subsets with a CD4+CD7- and CD4+CD26- phenotype and Sezary cell counts. Thirty-three of 49 (67%) cases of leukemic CTCL reacted with an anti-Vbeta antibody. When combined with reports from the literature, the frequency of Vbeta5 (probably Vbeta5.1) usage was relatively high when compared with Vbeta2 that is also frequently expressed by normal CD4+ T cells. The percentage of Vbeta+ cells correlated to the percentage of CD4+CD7- and CD4+CD26- cells for cases in which the neoplastic cells were deficient in expression of CD7 and CD26, respectively, but not the Sezary cell count. We hypothesize that the increased Vbeta5.1 usage in CTCL may be the result of depletion of Vbeta2 and other Vbeta-bearing T cells by staphylococcal superantigens prior to neoplastic transformation, resulting in a relative increase in the frequency of Vbeta5.1 usage in CTCL.
Vonderheid
Eric C
EC
Department of Dermatology, Johns Hopkins Medical Institutes, Baltimore, Maryland 21205, USA. evonder1@jhmi.edu
Boselli
Christine M
CM
Conroy
Michael
M
Casaus
Laurie
L
Espinoza
Lisa Cheley
LC
Venkataramani
Prakash
P
Bigler
Robert D
RD
Hou
J Steve
JS
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D019674:Genes, T-Cell Receptor beta / Q000276:immunology*; D006801:Humans; D007135:Immunoglobulin Variable Region / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012751:Sezary Syndrome / Q000276:immunology* / Q000503:physiopathology; D012878:Skin Neoplasms / Q000276:immunology* / Q000503:physiopathology; D018089:Superantigens / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology
D014408:Biomarkers, Tumor; D007135:Immunoglobulin Variable Region; D018089:Superantigens